Feedback activation of GATA1/miR-885-5p/PLIN3 pathway decreases sunitinib sensitivity in clear cell renal cell

Dayong Yao1, Shunyao Xia1, Chengjun Jin1

  • 1Department of Urology, The First Affiliated Hospital of Harbin Medical University , Harbin, China.

Insights

A new study reveals that decreased miR-885-5p levels correlate with poor outcomes in advanced renal cell carcinoma (RCC) patients treated with sunitinib, suggesting a novel therapeutic target for overcoming drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Sunitinib is a primary treatment for advanced renal cell carcinoma (RCC).
  • Drug resistance significantly limits sunitinib's clinical effectiveness.
  • Identifying resistance mechanisms and biomarkers is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of miR-885-5p in sunitinib resistance in clear cell renal cell carcinoma (ccRCC).
  • To elucidate the molecular mechanisms underlying miR-885-5p dysregulation and its impact on sunitinib sensitivity.

Main Methods:

  • Analysis of miR-885-5p expression in ccRCC patients treated with sunitinib.
  • In vitro and in vivo studies to assess the functional role of miR-885-5p.
  • Investigation of the GATA1/miR-885-5p/PLIN3 regulatory pathway.

Main Results:

  • miR-885-5p was downregulated in ccRCC patients with poor response to sunitinib.
  • Reduced miR-885-5p expression contributed to sunitinib resistance.
  • Sunitinib treatment decreased GATA1, leading to reduced miR-885-5p transcription.
  • miR-885-5p targets PLIN3, and its upregulation promotes lipid droplet formation, decreasing sunitinib sensitivity.

Conclusions:

  • The GATA1/miR-885-5p/PLIN3 pathway is implicated in sunitinib resistance in ccRCC.
  • miR-885-5p may serve as a predictive biomarker for sunitinib treatment.
  • Targeting this pathway offers a potential therapeutic strategy for overcoming sunitinib resistance in ccRCC.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.3K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.5K